文献速递免疫规划慢病防控与筛查

补充胆钙化醇改善血液透析患者乙型肝炎疫苗接种反应:首个随机开放标签先导研究(DeVitaHep)

Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep).
PubMed 文献 · Vaccine · 2021-11-19

这项随机开放标签先导研究纳入40例未接种疫苗且25(OH)D不足(<30 ng/mL)的血液透析患者,补充组口服胆钙化醇28,000 IU每周最多12周后再接种乙型肝炎疫苗,对照组随机后立即接种。37例完成随机分组(对照组17例、补充组20例),两组血清转换率(35.3% vs 27.3%,p=0.704)和血清保护率(23.5% vs 18.2%)均无显著差异,补充安全且无治疗相关不良事件。

要点

  • 高剂量口服胆钙化醇未改善维生素D不足血液透析患者的乙型肝炎疫苗反应。
  • 血清转换率补充组35.3% vs 对照组27.3%,p=0.704,无显著差异。
  • 血清保护率补充组23.5% vs 对照组18.2%,两组无显著差异。

核心结论

  • 在这项小型先导研究中,高剂量口服胆钙化醇补充未改善维生素D不足血液透析患者的乙型肝炎疫苗接种反应。

研究设计与样本

  • 随机开放标签先导研究,纳入40例未接种疫苗且25(OH)D不足(<30 ng/mL)的血液透析患者。
  • 补充组口服胆钙化醇28,000 IU每周,最多12周,达到25(OH)D>30 ng/mL或完成三个月补充后接种乙型肝炎疫苗(HBvaxPRO 40 µg肌内注射,第0、1、6个月)。
  • 对照组随机后立即接种乙型肝炎疫苗。
  • 完成疫苗接种疗程后八周检测抗乙型肝炎抗体滴度(anti-HBs)。
  • 37例(26男、11女)患者接受随机分组,年龄65(13.5)岁,对照组17例、补充组20例。

主要发现

  • 补充12周后,补充组平均(SD)25(OH)D浓度从15.0(8.0)ng/mL升至31.0(7.1)ng/mL,对照组从14.0(7.1)mg/mL变为11.6(7.5)mg/mL(原文此处对照组单位写作mg/mL)。
  • 血清转换(anti-HBs滴度≥10 IU/L)补充组6例(35.3%)vs 对照组3例(27.3%),p=0.704。
  • 血清保护(anti-HBs滴度>100 IU/L)补充组4例(23.5%)vs 对照组2例(18.2%),两组无显著差异。
  • 胆钙化醇补充安全,无治疗相关不良事件。

局限性

  • 原文称本研究为小型先导研究(small pilot study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with advanced chronic kidney disease should be vaccinated against hepatitis B. In observational studies vitamin D insufficiency is associated with a reduced seroconversion rate. The effect of cholecalciferol supplementation on hepatitis B vaccination response in haemodialysis patients with vitamin D insufficiency is unknown. METHODS: In this randomized open label pilot study 40 unvaccinated haemodialysis patients with 25(OH)D insufficiency (<30 ng/mL) were enrolled. In the supplementation group, we administered cholecalciferol orally in a dose of 28,000 IU weekly for a maximum of 12 weeks. Hepatitis B vaccination (HBvaxPRO 40 µg i.m. months 0, 1, 6) was performed after achieving a 25(OH)D level >30 ng/mL or after completing three months of supplementation despite failure to achieve the target level. In the control group, patients were vaccinated immediately after randomization. Anti-hepatitis B-antibody titer (anti-HBs) was measured eight weeks after completing the vaccination course. RESULTS: Thirty-seven (26 male, 11 female) patients aged 65 (13.5) years underwent randomization with 17 patients allocated to the control group and 20 patients included in the supplementation group. After 12 weeks of cholecalciferol supplementation, mean (SD) 25(OH)D concentration increased from 15.0 (8.0) to 31.0 (7.1) ng/mL, but remained unchanged in the control group (14.0 (7.1) to 11.6 (7.5) mg/mL). Neither the number of patients with seroconversion (anti-HBs titer ≥ 10 IU/L; n = 6 (35.3%) vs n = 3 (27.3%), p = 0.704), nor the number of patients with seroprotection (anti-HBs titer >100 IU/L; n = 4 (23.5%) vs n = 2 (18.2%) differed between treatment groups. Cholecalciferol supplementation was safe without treatment-related adverse events. CONCLUSION: In this small pilot study, high-dose oral cholecalciferol supplementation did not improve the hepatitis B vaccination response in haemodialysis patients with vitamin D insufficiency. This clinical trial was registered within EudraCT (EudraCT number 2011-004621-26).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hafner-Giessauf H, Horn S, Schwantzer G, et al. Cholecalciferol supplementation to improve the hepatitis B vaccination response in hemodialysis patients: A first randomized open label pilot study (DeVitaHep). Vaccine. 2021. PMID: 34802788. doi:10.1016/j.vaccine.2021.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。